Bicycle Therapeutics plc (BCYC)

Bicycle Therapeutics plc (BCYC) is a healthcare company (biotechnology) based in the United Kingdom. The share price is $3.16, down 0.63% on the day, which values the company at $221.5M. Price as of 17 Nov 2026, 17:31 UTC, from Yahoo Finance.

Key facts

Share price
$3.16−0.63% today
Market value
$221.5M
Funk Score
51/100
Against its own history
Well below its usual priceusual price $20.13
200-week average
$14.3278% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Bicycle Therapeutics plc in more detail

BCYC trades at -1.3× next year's expected earnings, 2.7× sales. Measured against its own history, the price is 84% below what its usual multiples would imply ($20.13) — well below its usual price. It sits 78% below its 200-week average of $14.32.

Over the last five fiscal years Bicycle Therapeutics plc has compounded revenue 47.5% a year. Its Funk Score is 51 out of 100 (financial strength 2.8, profitability 2.5, growth 10.0, value 5.0, each out of 10).

In its favour: Operating margin is expanding; Five straight years of revenue growth. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

1 of the superinvestors tracked here hold BCYC, including Julian and Felix Baker (0.2% of the portfolio).

Superinvestors holding BCYC

1 of the investors tracked here report a position in their latest 13F filing.

Bicycle Therapeutics plc (BCYC): questions and answers

What is Bicycle Therapeutics plc's market cap?

Bicycle Therapeutics plc is valued at $221.5M at a share price of $3.16.

Is BCYC overvalued or undervalued?

Against its own history, BCYC is well below its usual price: the price is 84% below the $20.13 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is BCYC above its 200-week moving average?

No. BCYC is 77.9% below its 200-week average of $14.32. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Bicycle Therapeutics plc growing?

Over the last five fiscal years Bicycle Therapeutics plc's revenue grew 47.5% a year.

Does BCYC pay a dividend?

Bicycle Therapeutics plc does not currently pay a regular dividend.

Which famous investors own BCYC?

In their latest quarterly filings, Julian and Felix Baker (0.2% of the portfolio) hold BCYC. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Bicycle Therapeutics plc (BCYC) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BCYC

Underlying data: Yahoo Finance; company filings with the SEC.